Alzheimer's Disease
Technology use highly accepted by caregivers, those with AD-related agitation
Technology was found to be both easy to use and highly acceptable in a cohort of those with Alzheimer’s-related agitation and their caregivers, according to a poster presentation at CTAD.
Customized transcription linked to more accurate speech-based AD screening
A customized speech transcription model logged roughly 30% fewer errors compared with manual or automated methods and may be a more effective tool in assessing verbal Alzheimer’s disease-related impairment.
Computerized training improved cognitive performance in those with MCI
Individuals with mild cognitive impairment performed faster on functional skills assessments and logged fewer dropouts when undergoing concurrent burst cognitive training, according to a poster from CTAD.
Participation in digital cognitive test, biomarker assays linked to AD study enrollment
Participation in memory-based digital cognitive testing and blood-based biomarker assays for Alzheimer’s-related pathology was linked to successful enrollment into clinical trials for disease-modifying treatment, according to research.
FDA grants orphan drug designation to oral Huntington’s disease therapy
The FDA has granted orphan drug designation to an investigational oral therapeutic for the treatment of Huntington’s disease, according to the manufacturer.
FDA accepts IND with partial clinical hold for oral small molecule Alzheimer’s treatment
The FDA has accepted an investigational new drug application for VG-3927, an oral small molecule TREM2 agonist for the potential treatment of Alzheimer’s disease, according to the manufacturer.
Is menopausal hormone therapy linked with dementia risk? Studies offer conflicting views
PHILADELPHIA — The short-term effects of postmenopausal hormone therapies on the vascular system and the brain may differ from long-term effects and could be influenced by HT formulation and administration route, according to a speaker.
FDA grants 510(k) clearance for Alzheimer’s, dementia diagnosis software
The FDA has granted 510(k) clearance to German medical technology company AIRAmed for its medical image management and processing system designed to assist physicians in early detection of Alzheimer’s disease and other dementias.
VIDEO: Clear communication, outreach key to boost inclusivity in clinical research
PHILADELPHIA — In order for underserved communities to successfully engage in clinical research, clear communication and multidisciplinary outreach by the medical community is necessary, according to a speaker.
Patient comfort, knowledge drive philosophy in early diagnosis of neuro conditions
PHILADELPHIA — Consideration of multiple factors among patients, families and health care providers drive the process of diagnosing preclinical or prodromal neurologic disease, which should be tailored to the individual, a speaker said.